Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651453 · ClinicalTrials.gov registry record · NA
OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings
A NA study of HIV Infections and Substance Abuse, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT03651453: Completed NA study of HIV Infections and Substance Abuse, sponsored by Yale University.
NCT03651453 is a NA study of HIV Infections and Substance Abuse that has completed, run by Yale University. The registered enrollment target is 164 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03651453, a NA study of HIV Infections and Substance Abuse, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
To develop and test the effect of a patient-centered HIV prevention decision aid on HIV pre-exposure prophylaxis (PrEP) uptake among women with substance use disorders (SUD) in treatment.
Primary Outcome
PrEP uptake is measured by attending an appointment with a provider for the purposes of starting PrEP.
Conditions Studied
Interventions
- BEHAVIORAL Standard care
- BEHAVIORAL Decision aid
Study Locations (1)
Connecticut
- Yale AIDS Program - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2020-06-11 |
| Phase | NA |
What the finished NCT03651453 record still lists
NCT03651453 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Standard care is the first listed.
NCT03651453 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03651453 about?
NCT03651453 is a clinical study titled "OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings". To develop and test the effect of a patient-centered HIV prevention decision aid on HIV pre-exposure prophylaxis (PrEP) uptake among women with substance use disorders (SUD) in treatment.
What is the current status of trial NCT03651453?
This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2018-10-15. Estimated completion is 2020-06-11.
What conditions does trial NCT03651453 study?
This clinical trial studies the following conditions: HIV Infections, Substance Abuse.
What interventions are being tested in trial NCT03651453?
The interventions under investigation include: Standard care (BEHAVIORAL), Decision aid (BEHAVIORAL).
Who is sponsoring clinical trial NCT03651453?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03651453 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03651453's enrollment target sits among peer trials
164 203rd of 542 higher than 340 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI